このアイテムのアクセス数: 45

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s41598-024-76269-1.pdf3.16 MBAdobe PDF見る/開く
タイトル: Development of a high-throughput screening system targeting the protein-protein interactions between PRL and CNNM
著者: Funato, Yosuke  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-4288-7717 (unconfirmed)
Mimura, Mai
Nunomura, Kazuto
Lin, Bangzhong
Fujii, Shintarou
Haruta, Junichi
Miki, Hiroaki
著者名の別形: 船戸, 洋佑
三木, 裕明
キーワード: Phosphatase of regenerating liver (PRL)
Cyclin M (CNNM)
Protein-protein interaction (PPI)
Homogenous time-resolved fluorescence resonance energy transfer (HTR-FRETHTRF)
Compound screening
発行日: 25-Oct-2024
出版者: Springer Nature
誌名: Scientific Reports
巻: 14
論文番号: 25432
抄録: Phosphatase of regenerating liver (PRL) is an oncogenic protein that promotes tumor progression by directly binding to cyclin M (CNNM) membrane proteins and inhibiting their Mg2+ efflux activity. In this study, we have developed a high-throughput screening system to detect the interactions between PRL and CNNM proteins based on homogenous time-resolved fluorescence resonance energy transfer (HTR-FRET, HTRF). We optimized the tag sequences attached to the recombinant proteins of the CNNM4 CBS domains and PRL3 lacking the carboxyl terminal CAAX motif, and successfully detected the interaction by observing the FRET signal in the mixture of the tagged proteins and fluorophore-conjugated antibodies. Moreover, we performed compound library screening using this system and discovered several compounds that could efficiently inhibit the PRL-CNNM interaction. Characterization of one candidate compound revealed that it was relatively stable compared with thienopyridone, a known inhibitor of the PRL-CNNM interaction. The candidate compound can also inhibit PRL function in cells: suppression of CNNM-dependent Mg²⁺ efflux, and has sufficient in vitro drug metabolism and pharmacokinetic properties. Overall, these results demonstrate the effectiveness of this screening system for identifying novel inhibitors of the PRL-CNNM interaction, which could contribute to the development of novel anti-cancer drugs.
著作権等: © The Author(s) 2024
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
URI: http://hdl.handle.net/2433/290333
DOI(出版社版): 10.1038/s41598-024-76269-1
PubMed ID: 39455715
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons